AstraZeneca plc 15.5% Potential Decrease Indicated by UBS

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

AstraZeneca plc with EPIC/TICKER (LON:AZN) has had its stock rating noted as ‘Unchanged’ with the recommendation being set at ‘SELL’ today by analysts at UBS. AstraZeneca plc are listed in the Health Care sector within UK Main Market. UBS have set their target price at 7300 GBX on its stock. This would imply the analyst believes there is a potential downside of -15.5% from today’s opening price of 8635 GBX. Over the last 30 and 90 trading days the company share price has increased 123 points and increased 1250 points respectively. The 52 week high for the stock is 9335 GBX while the year low share price is currently 5871 GBX.

AstraZeneca plc has a 50 day moving average of 8,228.52 GBX and the 200 Day Moving Average price is recorded at 7,605.31. There are currently 1,312,261,399 shares in issue with the average daily volume traded being 2,396,933. Market capitalisation for LON:AZN is £114,744,136,728 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.
    AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients.
    AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy.

      Search

      Search